Maria D Ribadeneira

US Patent:

20220304987, Sep 29, 2022

Filed:

Mar 18, 2022

Appl. No.:

17/698505

Inventors:

- Watertown MA, US
Neal Green - Newton MA, US
Gary Gustafson - Ridgefield CT, US
Gary Marshall - Watertown MA, US
Lorna Mitchell - Cambridge, NZ
David Richard - Littleton MA, US
Zhongguo Wang - Lexington MA, US
Sanjeev Forsyth - Milton MA, US
Patrick F. Kelly - Concord MA, US
Madhu Mondal - Winchester MA, US
Maria Ribadeneira - Cambridge MA, US
Patricia Schroeder - Somerville MA, US

International Classification:

A61K 31/436
A61P 9/00

Abstract:

The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

US Patent:

20200405699, Dec 31, 2020

Filed:

Sep 1, 2020

Appl. No.:

17/008787

Inventors:

- Watertown MA, US
Neal GREEN - Newton MA, US
Gary GUSTAFSON - Ridgefield CT, US
Gary MARSHALL - Watertown MA, US
Lorna MITCHELL - West Beach, AU
David RICHARD - Littleton MA, US
Zhongguo WANG - Lexington MA, US
Sanjeev FORSYTH - Milton MA, US
Patrick F. KELLY - Concord MA, US
Madhu MONDAL - Winchester MA, US
Maria RIBADENEIRA - Cambridge MA, US
Patricia SCHROEDER - Somerville MA, US

International Classification:

A61K 31/436
A61P 7/06
A61K 9/00

Abstract:

Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

US Patent:

20190343813, Nov 14, 2019

Filed:

Nov 7, 2017

Appl. No.:

16/348359

Inventors:

- Cambridge MA, US
Thomas Wai-Ho Lee - Lexington MA, US
Rajesh R. Iyengar - West Newton MA, US
Nicholas Robert Perl - Somerville MA, US
Peter Germano - Newton MA, US
Maria D. Ribadeneira - Cambridge MA, US
Kim Tang - Belmont MA, US

Assignee:

Cyclerion Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 31/437
A61K 31/519
A61K 31/5025
A61K 31/506
A61P 25/28

Abstract:

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′,5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.